Necitumumab-Gemcitabine-Cisplatin
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Squamous Cell Lung Cancer
Conditions
Squamous Cell Lung Cancer
Trial Timeline
May 29, 2018 → Sep 26, 2019
NCT ID
NCT03574818About Necitumumab-Gemcitabine-Cisplatin
Necitumumab-Gemcitabine-Cisplatin is a phase 2 stage product being developed by Eli Lilly for Squamous Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03574818. Target conditions include Squamous Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03574818 | Phase 2 | Terminated |
Competing Products
20 competing products in Squamous Cell Lung Cancer